The United States has unveiled a phased tariff regime on imported generic medicines that could significantly reshape global pharmaceutical supply chains and place fresh pressure on India's export-driven drug industry. Announcing the policy on his Truth Social platform, US President Donald Trump said imported generic medicines would continue to enjoy zero tariffs for two years beginning August 1, 2026. From August 2028, however, imports will attract a 100 per cent tariff for one year, rising to 200 per cent thereafter. Trump said the measure is designed to encourage pharmaceutical manufacturers to establish production facilities in the United States, warning that companies failing to relocate manufacturing during the transition period would face steep import duties. The administration has clarified that its existing policy on patented and innovative medicines will remain unchanged, with the new tariff regime targeting only the generic drug segment.
The announcement has drawn immediate attention in India, which is the world's largest supplier of affordable generic medicines and the single biggest exporter of these products to the American market. Indian pharmaceutical companies account for nearly 40 per cent of generic medicines consumed in the United States by volume, supplying treatments for chronic conditions including diabetes, hypertension, cardiovascular disease, cancer, mental health disorders and infectious diseases. According to industry estimates, India's pharmaceutical exports to the US touched nearly $9.7 billion in 2024-25, representing about 38 per cent of the country's total pharmaceutical exports. The dependence is particularly pronounced in low-cost medicines, with Indian manufacturers also dominating supplies of several essential therapies, including oral contraceptive pills. Analysts say any substantial disruption to this trade could affect both Indian exporters and the affordability of medicines in the US, where generic drugs account for the overwhelming majority of prescriptions.
The long implementation timeline, however, means the policy's ultimate impact remains uncertain. The two-year grace period provides multinational and Indian drugmakers time to evaluate whether establishing manufacturing facilities in the United States is commercially viable or whether alternative supply-chain arrangements can reduce the tariff burden. Industry observers also note that India and the United States had earlier agreed to pursue negotiated outcomes on generic pharmaceuticals and active pharmaceutical ingredients under their bilateral trade framework, leaving open the possibility of further discussions before the tariffs take effect. Several global manufacturers have already indicated that they are awaiting detailed implementation guidelines before assessing investment plans. Even so, the announcement signals Washington's continued push to bring pharmaceutical manufacturing back to domestic soil, a strategy that could reshape one of the world's most integrated healthcare supply chains over the coming years.